<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02719210</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-ALF-02</org_study_id>
    <nct_id>NCT02719210</nct_id>
  </id_info>
  <brief_title>High Volume Plasma Exchange in Children With Acute Liver Failure and Acute on Chronic Liver Failure</brief_title>
  <official_title>High Volume Plasma Exchange in Children With Acute Liver Failure and Acute on Chronic Liver Failure-A Prospective Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      All the children with acute liver failure who are candidates for transplant but have
      constraints for transplant will be randomized either to receive standard medical therapy or
      high volume plasma exchange along with standard medical therapy with the aim to assess the
      effect of high volume plasma exchange on transplant free survival.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Actual">November 30, 2018</completion_date>
  <primary_completion_date type="Actual">November 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transplant free Survival.</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Transplant free survival</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival after liver transplant with or without High Volume Plasma Exchange.</measure>
    <time_frame>30 days post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of organ dysfunction (other than liver and Central Nervous System).</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of organs (other than liver and CNS) affected in children with organ dysfunction.</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of High Volume Plasma Exchange related complications- Major/Minor.</measure>
    <time_frame>within 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemodynamic parameters and Hepatic Encephalopathy (HE) before and after in the High Volume Plasma Exchange group.</measure>
    <time_frame>0 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemodynamic parameters and Hepatic Encephalopathy (HE) before and after in the High Volume Plasma Exchange group.</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Laboratory parameters - Bilirubin, INR and Ammonia in control group.</measure>
    <time_frame>0 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Laboratory parameters - Bilirubin, INR and Ammonia- in control group.</measure>
    <time_frame>5 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the levels of IL-6 and TNF alpha (Tumor Necrosis Factor) in HVPE arm from baseline till within 24-hours of the last session of High Volume Plasma Exchange.</measure>
    <time_frame>within 24-hours of the last session of High Volume Plasma Exchange</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the levels of IL-6 and TNF alpha (Tumor Necrosis Factor) in control arm from baseline till 5 days.</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Acute Liver Failure</condition>
  <arm_group>
    <arm_group_label>High Volume Plasma Exchange with Standard Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Treatment is defined as anti raised Intra-cranial pressure
Elective positive pressure ventilation in hepatic encephalopathy grade 3 or 4 and in those with features of raised ICP (Intra-cranial pressure).
Mannitol
Hypertonic 3% Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High Volume Plasma Exchange</intervention_name>
    <arm_group_label>High Volume Plasma Exchange with Standard Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypertonic 3% saline</intervention_name>
    <arm_group_label>Standard Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mannitol</intervention_name>
    <arm_group_label>Standard Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Elective positive pressure ventilation</intervention_name>
    <arm_group_label>Standard Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Children ≥ 10kg with ALF with INR ≥ 4 or INR ≥ 3 with Hepatic Encephalopathy.

        Exclusion Criteria:

          1. Evidence of active infection (Age specific neutrophilic leucocytosis (ANC) and
             procalcitonin ≥ 2 and/or focus of active infection

          2. Refusal of consent or assent (annexure 3)

          3. Liver resections with liver failure

          4. Patients with clinical suspicion of irreversible brain injury

          5. Patients with acute kidney injury
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Arti Pawaria, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Liver and Biliary Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>February 17, 2016</study_first_submitted>
  <study_first_submitted_qc>March 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2016</study_first_posted>
  <last_update_submitted>December 4, 2018</last_update_submitted>
  <last_update_submitted_qc>December 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
    <mesh_term>Liver Failure, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mannitol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

